参考文献: Xia Song, Lin Qiong, Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.[J] .Technol Cancer Res Treat, 2022, 21: 15330338221090351. 材料由阿斯利康支持,仅供医疗卫生专业人士参考 过期日期2023-8-10 审批编号CN-100137...
A.; Fernandez, K.J.; Chia, K.M.; Halilovic, E.; Segara, D.; Parker, A.; et al. MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer. Breast Cancer Res. 2020, 22, 87. ...
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that ...
28. LHRH-agonists in Early Breast Cancer Overview group, et al. Use of luteinising hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of ...
[2]Yu KD, Cai YW, Wu SY, Shui RH, Shao ZM. Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. Cancer Commun (Lond). 2021;41(10):968-980. doi:10.1002/cac2.12191 [3]Poterala JE, Wisinski KB. Ab...
"This paper identifies an important missed opportunity—the treatment of aggressive ER+ breast cancer with immune checkpointtherapy. While the current emphasis for immunotherapy is almost entirely on triple-negative breast cancer, we think that this focus excludes as many as half of the patients who...
In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.
(Herceptin) has been shown to dramatically reduce the risk of the cancer coming back. It‘s standard treatment to give this medication along withchemotherapyafter surgery to people with breast cancer that’s spread to other areas. It can also be used for early-stage breast cancer. But there ...
(Medical Xpress) -- Cell cultures are homogeneous. Human tumors are not. A University of Colorado Cancer Center study recently published in the journalBreast Cancer Research and Treatmentreports the development of human-derived estrogen-positive (ER+) breast cancer models that retain their heterogeneit...
Partridge continues. This often includes managing sexual health, psychological stress, and the long-term effects of therapies. Therefore, the care of young breast cancer patients should be holistic and proactive, addressing both immediate treatment concerns and future quality of life, ...